Apixaban
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Apixaban: From Thromboembolic Conditions to Migraine Disorder
One-Sentence Summary
Apixaban is an oral direct factor Xa inhibitor (anticoagulant) marketed in Singapore as Eliquis. The TxGNN model predicts it may be effective for migraine disorder, but the supporting evidence is weak: 1 clinical trial (not actually about migraine) and 3 publications (two case reports and one small retrospective study), with the case reports suggesting no benefit or even worsening on apixaban.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence data compiled for this report (the approved indication text is blank) |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 99.02% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, apixaban is a direct factor Xa inhibitor that blocks thrombin generation and clot formation.
The proposed link to migraine is indirect and speculative. Migraine with aura has been associated with patent foramen ovale (PFO), paradoxical microemboli and prothrombotic states such as antiphospholipid antibodies. Anticoagulation could therefore plausibly help in a selected thrombotic or PFO-related subset of patients.
However, the available case reports point the other way. One describes migraine with aura worsening after starting apixaban. Another describes a patient whose migraine with aura remained in remission for 12 years on warfarin, returned within 3 weeks of switching to apixaban, and resolved again after warfarin was resumed. The very high TxGNN score is therefore not supported by clinical data.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00562289 | Phase 3 | Completed | 664 | PFO closure or anticoagulants vs antiplatelet therapy to prevent recurrent stroke in patients with PFO. Studies cryptogenic stroke, not migraine; apixaban was not tested for migraine. |
This trial has low relevance (grade C) and does not support the migraine prediction.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33402037 | 2021 | Retrospective study (75 patients) | Lupus | Antithrombotic therapy in refractory migraine with antiphospholipid antibodies; small, specific subgroup, not apixaban-specific |
| 28960288 | 2017 | Case report | Headache | Migraine with aura in remission on warfarin returned on apixaban and resolved again after warfarin resumed |
| 37582651 | 2023 | Case report | The Neurologist | Migraine with aura worsened after starting apixaban; literature on direct oral anticoagulants in migraine is scarce and controversial |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN14279P | Eliquis Tablet 2.5mg | Film-coated tablet | Not available |
| SIN14407P | Eliquis Tablet 5mg | Film-coated tablet | Not available |
Both licences are valid single-ingredient oral products. The marketing authorisation holders listed are Bristol-Myers Squibb Manufacturing Company Unlimited Company and Pfizer Ireland Pharmaceuticals.
Safety Considerations
Drug Interactions: 100 interactions were identified. Major-level interactions in the data compiled for this report include:
- Acetylsalicylic acid (aspirin)
- Cobicistat
- Deferasirox
- Ibritumomab tiuxetan
- Tositumomab (including I-131 tositumomab)
Moderate-level interactions include aprepitant, clarithromycin, clotrimazole, dexamethasone, miconazole, rolapitant, fenfluramine and sugammadex, among others.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a very high model score only. The sole registered trial studies stroke prevention rather than migraine, and the case reports suggest no benefit or possible worsening on apixaban. Bleeding risk is also a concern for a non-life-threatening condition such as migraine.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA, which are currently missing
- Mechanism of action data
- A clearly defined migraine subgroup (for example PFO-related or antiphospholipid-antibody-positive) with a plausible rationale
- Controlled clinical data in that subgroup, including a bleeding risk-benefit assessment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.